Medley Pharmaceuticals Ltd. has achieved a remarkable World Record for the Maximum Neuropathic Patients Screened Using Vibration Sensory Devices During Awareness Week. The nationwide awareness initiative successfully screened 18,943 neuropathic patients through 552 screening camps, highlighting the importance of early detection and preventive healthcare.
The large-scale campaign utilized advanced vibration sensory devices, including Vibrasense, Vibrasense T, HCP Sensitometer, and Biothesiometer, to assess patients for signs of neuropathy. The screenings were conducted by healthcare professionals to facilitate timely identification of nerve damage and encourage appropriate medical intervention.
Organized as part of an awareness week, the initiative aimed to enhance both public and clinical awareness about neuropathy while emphasizing the importance of routine screening for early diagnosis and effective disease management. The campaign also encouraged individuals, particularly those at higher risk, to adopt proactive healthcare practices to prevent long-term complications.
